Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Особенности выбора пероральной гормональной контрацепции
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: пероральная контрацепция, таблетки, дезогестрел.
________________________________________________
Reasonable approach to a contraceptive method use desirebleallows to avoid an undesired pregnancy. Pharmacological properties of modern hormonal oral contraceptives promote their widespread application in women with genital and extragenital disturbances. Progestogen-only pill (POP) is alternative kind of contraception for women with contraindications to estrogen use (on an exampleofthe Lactinette tablets).
Key words: оral contraception, pills, desogestrel.
2. Критерии приемлемости использования методов контрацепции. ВОЗ, 2009.
3. WHO. Medical eligibility criteria for contraceptive use. 4th edition. Geneva 2009.
4. Rice CF, Killick SR, Dieben T, Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 mcg and levonorgestrel 30 mcg daily. Hum Reprod 1999; 14: 982–5.
5. Winkler UH, Howie H, Buehler K et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 mcg desogestrel and 30 mcg levonorgestrel. Contraception 1998; 57: 385–92.
6. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 mcg/day) or levonorgestrel (30 mcg/day) on lipid metabolism. Contraception 2001; 64 (5): 295–300.
7. Kivelae A, Ruuskanen M, Aegren U, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 mcg/day) or levonorgestrel (30 mcg/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2001; 6: 71–7.
________________________________________________
1. Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс-информ, 2010.
2. Критерии приемлемости использования методов контрацепции. ВОЗ, 2009.
3. WHO. Medical eligibility criteria for contraceptive use. 4th edition. Geneva 2009.
4. Rice CF, Killick SR, Dieben T, Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 mcg and levonorgestrel 30 mcg daily. Hum Reprod 1999; 14: 982–5.
5. Winkler UH, Howie H, Buehler K et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 mcg desogestrel and 30 mcg levonorgestrel. Contraception 1998; 57: 385–92.
6. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 mcg/day) or levonorgestrel (30 mcg/day) on lipid metabolism. Contraception 2001; 64 (5): 295–300.
7. Kivelae A, Ruuskanen M, Aegren U, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 mcg/day) or levonorgestrel (30 mcg/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2001; 6: 71–7.
ФГБУ Научный центр экспертизы средств медицинского применения Минздравсоцразвития РФ
________________________________________________
V.V.Yaglov